System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Rupert W Leong is an expert in Gastroenterology at Concord Repatriation General Hospital (Australia). As of October 2026, ScienceLeadR ranks Rupert W Leong in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Rupert W Leong has authored 494 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 1 of them ongoing. SLR score: 1,955 (community average: 125). How the SLR is computed.

LeadR Profile

Rupert W Leong Concord Repatriation General Hospital Australia
1 955 ScienceLeadR Reputation 1955

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Hepatology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Concord Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 494

Citations

Citations: 16 924 1st author: 32 Last author: 175 Unique author: 10

Main journals

J Crohns Colitis 84
Gastroenterology 78
J Gastroenterol Hepatol 61
Am J Gastroenterol 26
Gastrointest Endosc 20

Best Journals

Lancet Gastroenterol Hepatol 9
Gastroenterology 3
N Engl J Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Dietary beliefs, barriers, and acceptability of diet in adult patients with inflammatory bowel disease-A multicenter survey of the Asia-Pacific region.
PMID 42502167 — diet, food, parenteral nutrition, inflammatory bowel diseases, patient preference, meals, enteral nutrition		Nutr Clin Pract20260
International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials.
PMID 42463422 — inflammatory bowel diseases, therapeutics		Gut20260
Off-label upadacitinib 60 mg daily in the rescue of refractory ulcerative colitis: an open-labeled cohort study.
PMID 42418656 — colitis, cohort studies, inflammatory bowel diseases, colitis, ulcerative		J Crohns Colitis20260
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
PMID 42413123 — colitis, inflammatory bowel diseases, therapeutics, colitis, ulcerative, small molecules		J Crohns Colitis20267
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.
PMID 42381162 — colitis, appendectomy, inflammatory bowel diseases, therapeutics, colitis, ulcerative		J Crohns Colitis20263

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 8
Phase 3 5
N/A 2
Phase 4 2
Phase 2/Phase 3 1

By status:

Completed 14
Active not recruiting 1
Recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 18

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 3
multicentric5to9 0
multicentricup10 12

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study on the Safety of TAK 279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn s Disease
NCT06233461 — safety, crohn disease, pharmaceutical preparations, drug therapy, capsules, research, therapeutics		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS